Covered recipient · General Payments record
TIMOTHY R SMITH
Allopathic & Osteopathic Physicians Internal Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$65,207.08
75 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $59,487.50 | 49 |
| Consulting Fee | $3,820.00 | 3 |
| Travel and Lodging | $1,312.88 | 8 |
| Food and Beverage | $545.20 | 14 |
| Education | $41.50 | 1 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Lilly USA, LLC | $33,076.82 | 31 |
| Biohaven Pharmaceuticals, Inc. | $16,376.09 | 28 |
| Amgen Inc. | $7,700.81 | 8 |
| AbbVie Inc. | $4,246.88 | 5 |
| Teva Pharmaceuticals USA, Inc. | $2,020.00 | 1 |
| Allergan, Inc. | $1,750.00 | 1 |
| Lundbeck LLC | $36.48 | 1 |
Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
TIMOTHY R SMITH
NPI 1275502049 · CMS profile ID 148468
Allopathic & Osteopathic Physicians / Internal Medicine
SAINT PETERS, MO
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1275502049?year=2021&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- TIMOTHY R SMITH, NPI 1275502049, CMS profile ID 148468. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1275502049?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). TIMOTHY R SMITH, NPI 1275502049, CMS profile ID 148468. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1275502049?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- TIMOTHY R SMITH, NPI 1275502049, CMS profile ID 148468, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1275502049?year=2021&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
75 matching records · $65,207.08 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–75 of 75.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Lilly USA, LLC | $2,700.00 | 03/25/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818706941 | CMS |
| Biohaven Pharmaceuticals, Inc. | $425.00 | 03/22/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 852629385 | CMS |
| Lilly USA, LLC | $1,200.00 | 03/19/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818816899 | CMS |
| Lilly USA, LLC | $2,700.00 | 03/17/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818707943 | CMS |
| Lilly USA, LLC | $1,200.00 | 03/17/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818707947 | CMS |
| Lilly USA, LLC | $1,200.00 | 03/11/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818814163 | CMS |
| Biohaven Pharmaceuticals, Inc. | $425.00 | 03/09/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 852629383 | CMS |
| Lilly USA, LLC | $41.50 | 03/09/2021 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818706943 | CMS |
| Biohaven Pharmaceuticals, Inc. | $1,275.00 | 03/08/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 852629381 | CMS |
| Biohaven Pharmaceuticals, Inc. | $425.00 | 03/05/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 852629379 | CMS |
| Lilly USA, LLC | $1,200.00 | 03/05/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818814161 | CMS |
| Lilly USA, LLC | $1,200.00 | 03/04/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818765787 | CMS |
| Biohaven Pharmaceuticals, Inc. | $1,500.00 | 02/24/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 852629377 | CMS |
| Lilly USA, LLC | $600.00 | 02/24/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818684779 | CMS |
| Lilly USA, LLC | $18.82 | 02/24/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818801445 | CMS |
| Lilly USA, LLC | $13.23 | 02/23/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818761839 | CMS |
| Biohaven Pharmaceuticals, Inc. | $425.00 | 02/19/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 852629375 | CMS |
| Lilly USA, LLC | $600.00 | 02/19/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818706945 | CMS |
| Lilly USA, LLC | $600.00 | 02/16/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818707945 | CMS |
| Biohaven Pharmaceuticals, Inc. | $425.00 | 02/15/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 852629373 | CMS |
| Biohaven Pharmaceuticals, Inc. | $1,700.00 | 02/10/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 852629369 | CMS |
| Biohaven Pharmaceuticals, Inc. | $19.30 | 02/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 852629371 | CMS |
| Biohaven Pharmaceuticals, Inc. | $425.00 | 02/09/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 852629367 | CMS |
| Biohaven Pharmaceuticals, Inc. | $1,275.00 | 01/11/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 852629365 | CMS |
| Allergan, Inc. | $1,750.00 | 01/08/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 792949949 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $1,600.00 | 3 |
| PY2025 | Principal investigator | $4,487,276.50 | 296 |
| PY2024 | Recipient | $113,132.20 | 11 |
| PY2024 | Principal investigator | $4,680,361.26 | 186 |
| PY2023 | Recipient | $109,639.43 | 22 |
| PY2023 | Principal investigator | $4,150,716.29 | 270 |
| PY2022 | Recipient | $10,267.00 | 8 |
| PY2022 | Principal investigator | $2,852,345.29 | 506 |
| PY2021 | Recipient | $200.00 | 1 |
| PY2021 | Principal investigator | $2,481,488.34 | 138 |
| PY2020 | Recipient | $10,145.59 | 7 |
| PY2020 | Principal investigator | $1,518,161.92 | 141 |
| PY2019 | Recipient | $4,893.84 | 4 |
| PY2019 | Principal investigator | $786,813.56 | 137 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
299 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $292.00 | 12/17/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762721 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $13.92 | 12/17/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762723 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $16.56 | 12/17/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762725 |
| Principal investigator 1 | Eli Lilly and Company | $43,177.60 | 12/16/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH LLC | A PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT AND OSTEOARTHRITIS OF THE KNEE: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO-CONTROLLED TRIAL (ATTAIN-OA PAIN) ; J2A-MC-GZT1 ; J2A-MC-GZT2 | No dispute reported | 06/30/2026 | 1187890342 |
| Principal investigator 1 | Merz Pharmaceuticals, LLC | $13,700.00 | 12/10/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH LLC | A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Chronic Migraine | No dispute reported | 06/30/2026 | 1232647518 |
| Principal investigator 1 | Merz Pharmaceuticals, LLC | $2,500.00 | 12/10/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH LLC | A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Chronic Migraine | No dispute reported | 06/30/2026 | 1232647520 |
| Principal investigator 1 | Merz Pharmaceuticals, LLC | $2,500.00 | 12/10/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH LLC | A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Episodic Migraine | No dispute reported | 06/30/2026 | 1232647522 |
| Principal investigator 1 | Merz Pharmaceuticals, LLC | $13,700.00 | 12/10/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH LLC | A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Episodic Migraine | No dispute reported | 06/30/2026 | 1232647524 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,820.00 | 12/03/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220813409 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 12/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220762669 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.96 | 11/19/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220762671 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $292.00 | 11/19/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220762673 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $13.92 | 11/19/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220762675 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $16.56 | 11/19/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220762677 |
| Principal investigator 1 | Eli Lilly and Company | $1,020.92 | 11/19/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH LLC | RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY4065967 FOR THE TREATMENT OF DIABETIC PERIPHERAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1187893354 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $19,076.00 | 11/13/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220813473 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,171.00 | 11/05/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220813407 |
| Principal investigator 1 | PFIZER INC. | $42,945.54 | 11/04/2025 | Non-covered Recipient Entity StudyMetrix Research LLC | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1228724472 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 11/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762709 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762711 |
| Principal investigator 1 | Amgen Inc. | $7,879.58 | 10/28/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH LLC | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity | No dispute reported | 06/30/2026 | 1246648842 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $58.30 | 10/27/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762713 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $292.00 | 10/27/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762715 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $13.92 | 10/27/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762717 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $8.28 | 10/27/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762719 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $259.74 | 10/27/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220762727 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $182.50 | 10/27/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220762729 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $525.00 | 10/27/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220813467 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $6,000.00 | 10/23/2025 | Non-covered Recipient Entity STUDY METRIX RESEARCH LLC | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With Established Cardiovascular Disease | No dispute reported | 06/30/2026 | 1190309452 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,660.00 | 10/21/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220813463 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $800.00 | 10/21/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220813465 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,500.00 | 10/17/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220813405 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $17,126.00 | 10/15/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220813399 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6,160.00 | 10/15/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220813401 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,500.00 | 10/15/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220813403 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $115.00 | 10/15/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220813445 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $50.00 | 10/15/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220813447 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6,292.00 | 10/15/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220813449 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $50.00 | 10/15/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220813451 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $345.00 | 10/15/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220813453 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $50.00 | 10/15/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220813455 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $50.00 | 10/15/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220813457 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $400.00 | 10/15/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220813459 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $900.00 | 10/15/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220813461 |
| Recipient | PFIZER INC. | $940.00 | 10/09/2025 | Covered Recipient Physician | ZAVEGEPANT CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228726963 |
| Recipient | PFIZER INC. | $330.00 | 10/09/2025 | Covered Recipient Physician | ZAVEGEPANT CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228727861 |
| Recipient | PFIZER INC. | $330.00 | 10/09/2025 | Covered Recipient Physician | ZAVEGEPANT CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228727863 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $390.00 | 10/03/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220813469 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,429.76 | 10/03/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220813471 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220762667 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 10/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762705 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762707 |
| Principal investigator 1 | Eli Lilly and Company | $111.45 | 09/30/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH LLC | A PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT AND OSTEOARTHRITIS OF THE KNEE: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO-CONTROLLED TRIAL | No dispute reported | 06/30/2026 | 1187893352 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,075.00 | 09/26/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220813395 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $75.00 | 09/26/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220813397 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $23.32 | 09/24/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220762661 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $219.00 | 09/24/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220762663 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.22 | 09/24/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220762665 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $36.50 | 09/24/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762703 |
| Principal investigator 1 | Amgen Inc. | $24,800.00 | 09/23/2025 | Non-covered Recipient Entity EXPERT RESEARCH SOLUTIONS LLC STUDYMETRIX CONSULTING | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity | No dispute reported | 06/30/2026 | 1246641341 |
| Principal investigator 1 | PFIZER INC. | $5,210.80 | 09/09/2025 | Non-covered Recipient Entity StudyMetrix Research LLC | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1228758770 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,300.00 | 09/08/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH, LLC | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215522094 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,113.00 | 09/08/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH, LLC | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215522096 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $203.00 | 09/08/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH, LLC | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215522098 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $8,334.00 | 09/03/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220813393 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762641 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220762643 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 09/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762697 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $23.32 | 08/26/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220762659 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $146.00 | 08/26/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762699 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.48 | 08/26/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762701 |
| Principal investigator 1 | PFIZER INC. | $30,699.20 | 08/26/2025 | Non-covered Recipient Entity StudyMetrix Research LLC | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1228785218 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $8,520.00 | 08/21/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220813443 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $269.00 | 08/19/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220813383 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $269.00 | 08/19/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220813385 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $269.00 | 08/19/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220813391 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $5,118.35 | 08/19/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease | No dispute reported | 06/30/2026 | 1190309006 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $269.00 | 08/07/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220813387 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $269.00 | 08/07/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220813389 |
| Principal investigator 1 | PFIZER INC. | $42,453.60 | 08/05/2025 | Non-covered Recipient Entity StudyMetrix Research LLC | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1228767371 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220762529 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 08/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762695 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $9,352.00 | 08/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220813381 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $492.00 | 07/28/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH, LLC | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215522086 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $756.44 | 07/28/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH, LLC | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215522088 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $812.00 | 07/28/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH, LLC | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215522090 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $73.00 | 07/28/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220762657 |
| Principal investigator 1 | Eli Lilly and Company | $11,865.00 | 07/28/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH LLC | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | No dispute reported | 06/30/2026 | 1187889616 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $3,000.00 | 07/25/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH, LLC | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215522080 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,500.00 | 07/25/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH, LLC | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215522082 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,500.00 | 07/25/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH, LLC | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215522084 |
| Principal investigator 1 | PFIZER INC. | $1,570.10 | 07/18/2025 | Non-covered Recipient Entity StudyMetrix Research LLC | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1228782437 |
| Principal investigator 1 | PFIZER INC. | $25,709.00 | 07/15/2025 | Non-covered Recipient Entity StudyMetrix Research LLC | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1228764301 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,180.00 | 07/09/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220813439 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $8,391.55 | 07/02/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH, LLC | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215522092 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220762645 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220762647 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220762649 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220762651 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $43.00 | 07/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220762653 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.94 | 07/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220762655 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $61.58 | 07/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762679 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762681 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762683 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762685 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762687 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 07/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762689 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $43.00 | 07/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762691 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.94 | 07/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762693 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $16,619.00 | 07/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220813377 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,600.00 | 07/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220813437 |
| Principal investigator 1 | PFIZER INC. | $27,484.80 | 06/26/2025 | Non-covered Recipient Entity StudyMetrix Research LLC | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1228792392 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $8,052.00 | 06/25/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220813431 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $36.50 | 06/24/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762637 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.74 | 06/24/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762639 |
| Principal investigator 1 | Amgen Inc. | $16,006.40 | 06/23/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity | No dispute reported | 06/30/2026 | 1246648854 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $5,000.00 | 06/20/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH, LLC | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215522008 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $150.00 | 06/20/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH, LLC | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215522010 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,085.00 | 06/12/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220813375 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,000.00 | 06/09/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH, LLC | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215522004 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $150.00 | 06/09/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220813423 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $8.00 | 06/09/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220813425 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,600.00 | 06/05/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220813373 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,600.00 | 06/05/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220813429 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,600.00 | 06/04/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220813371 |
| Principal investigator 1 | Eli Lilly and Company | $222,868.28 | 06/02/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH LLC | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY IN PARTICIPANTS WITH HYPERTENSION AND OBESITY OR OVERWEIGHT: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIALS (ATTAIN-HYPERTENSION). ISAS-GZL1;GZL2 | No dispute reported | 06/30/2026 | 1187890312 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220762507 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220762509 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220762511 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220762513 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 06/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762611 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762613 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762615 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762617 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762619 |
| Principal investigator 1 | PFIZER INC. | $14,149.10 | 05/31/2025 | Non-covered Recipient Entity StudyMetrix Research LLC | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1228764866 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $73.00 | 05/27/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220762523 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.48 | 05/27/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220762525 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $8.28 | 05/27/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220762527 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.96 | 05/27/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762629 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $73.00 | 05/27/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762631 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.48 | 05/27/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762633 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $8.28 | 05/27/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762635 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $136.00 | 05/26/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220813421 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $136.00 | 05/25/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220813419 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,209.00 | 05/19/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220813433 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $75.00 | 05/19/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220813435 |
| Principal investigator 1 | PFIZER INC. | $35,975.10 | 05/14/2025 | Non-covered Recipient Entity StudyMetrix Research LLC | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1228773149 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $80.00 | 05/12/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220813379 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $80.00 | 05/12/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220813441 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6,386.00 | 05/09/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220813417 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $175.16 | 05/06/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220813369 |
| Principal investigator 1 | PFIZER INC. | $23,524.90 | 05/06/2025 | Non-covered Recipient Entity StudyMetrix Research LLC | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1228772647 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6,225.00 | 05/05/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220813367 |
| Principal investigator 1 | PFIZER INC. | $69,871.90 | 05/03/2025 | Non-covered Recipient Entity StudyMetrix Research LLC | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1228772911 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220762499 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220762501 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220762503 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220762505 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 05/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762601 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762603 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762605 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762607 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762609 |
| Principal investigator 1 | Amgen Inc. | $23,769.00 | 04/24/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH LLC | A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus | No dispute reported | 06/30/2026 | 1246648838 |
| Principal investigator 1 | Eli Lilly and Company | $8,613.01 | 04/24/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH LLC | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY IN PARTICIPANTS WITH HYPERTENSION AND OBESITY OR OVERWEIGHT: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIALS (ATTAIN-HYPERTENSION). ISAS-GZL1;GZL2 | No dispute reported | 06/30/2026 | 1187890664 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $46.64 | 04/23/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220762515 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $159.84 | 04/23/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220762517 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $292.00 | 04/23/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220762519 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6.96 | 04/23/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220762521 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $199.80 | 04/23/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762621 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $620.50 | 04/23/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762623 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $26.10 | 04/23/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762625 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $33.12 | 04/23/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762627 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $376.80 | 04/23/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220813365 |
| Principal investigator 1 | Eli Lilly and Company | $2,019.36 | 04/23/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH LLC | RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN | No dispute reported | 06/30/2026 | 1187890340 |
| Principal investigator 1 | PFIZER INC. | $44,349.90 | 04/18/2025 | Non-covered Recipient Entity StudyMetrix Research LLC | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1228795997 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $3,386.34 | 04/17/2025 | Non-covered Recipient Entity STUDY METRIX RESEARCH LLC | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) | No dispute reported | 06/30/2026 | 1190307949 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,360.00 | 04/11/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220813363 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $9,718.00 | 04/11/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220813415 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,180.00 | 04/10/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220813413 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220762491 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220762493 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220762495 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220762497 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762591 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762593 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762595 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762597 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 04/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762599 |
| Principal investigator 1 | Novo Nordisk AS | $2,402.88 | 03/28/2025 | Non-covered Recipient Entity ROVIA STUDYMETRIX RESEARCH | NN9535-4984 | No dispute reported | 06/30/2026 | 1213816981 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $331.65 | 03/25/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220762487 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.00 | 03/25/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220762489 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $19.98 | 03/25/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762577 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $73.00 | 03/25/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762579 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $331.65 | 03/25/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762581 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.00 | 03/25/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762583 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.48 | 03/25/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762585 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.14 | 03/25/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762587 |
| Principal investigator 1 | Eli Lilly and Company | $857.06 | 03/25/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH LLC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | No dispute reported | 06/30/2026 | 1187890172 |
| Principal investigator 1 | Eli Lilly and Company | $3,897.52 | 03/25/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH LLC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | No dispute reported | 06/30/2026 | 1187891670 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,026.00 | 03/24/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220813427 |
| Principal investigator 1 | PFIZER INC. | $28,113.40 | 03/22/2025 | Non-covered Recipient Entity StudyMetrix Research LLC | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1228787134 |
| Principal investigator 1 | Eli Lilly and Company | $429.14 | 03/21/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH LLC | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187893346 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,085.00 | 03/13/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220813361 |
| Principal investigator 1 | Eli Lilly and Company | $8,424.00 | 03/10/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH LLC | A PHASE 3B, RANDOMIZED CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TIRZEPATIDE COMPARED TO SEMAGLUTIDE 2.4 MG IN ADULTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES (SURMOUNT-5) | No dispute reported | 06/30/2026 | 1187890718 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220762467 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220762469 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220762471 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220762473 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762553 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762555 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762557 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762559 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $86.00 | 03/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762561 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 03/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762563 |
| Principal investigator 1 | ABBVIE INC. | $575.00 | 02/27/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH LLC | M21-307 - Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine | No dispute reported | 06/30/2026 | 1202454511 |
| Principal investigator 1 | ABBVIE INC. | $3,706.50 | 02/27/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH LLC | M21-307 - Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine | No dispute reported | 06/30/2026 | 1202454521 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $73.00 | 02/25/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220762481 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6.96 | 02/25/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220762483 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $8.28 | 02/25/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220762485 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $58.30 | 02/25/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762569 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $73.00 | 02/25/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762571 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $10.44 | 02/25/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762573 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $8.28 | 02/25/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762575 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,280.00 | 02/20/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220813359 |
| Principal investigator 1 | Eli Lilly and Company | $1,772.66 | 02/14/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH LLC | A STUDY OF ORFORGLIPRON FOR THE MAINTENANCE OF BODY WEIGHT REDUCTION IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES (ATTAIN-MAINTAIN) | No dispute reported | 06/30/2026 | 1187890666 |
| Principal investigator 1 | PFIZER INC. | $12,761.00 | 02/14/2025 | Non-covered Recipient Entity StudyMetrix Research LLC | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1228761923 |
| Principal investigator 1 | Eli Lilly and Company | $51,683.00 | 02/04/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH LLC | A RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, TWO-ARM, PHASE 4 STUDY TO EVALUATE THE LONG-TERM EFFICACY AND SAFETY OF TIRZEPATIDE COMPARED WITH INTENSIFIED CONVENTIONAL CARE IN ADULTS WHEN INITIATING TREATMENT EARLY IN THE COURSE OF TYPE 2 DIABETES | No dispute reported | 06/30/2026 | 1187892572 |
| Principal investigator 1 | Eli Lilly and Company | $77,268.54 | 02/03/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH LLC | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187890716 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220762453 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220762455 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220762457 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220762459 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.94 | 02/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220762461 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $64.50 | 02/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220762463 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $21.50 | 02/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220762465 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762539 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762541 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762543 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762545 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 02/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762547 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.94 | 02/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762549 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $86.00 | 02/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762551 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $10,763.00 | 02/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220813357 |
| Principal investigator 1 | Eli Lilly and Company | $645.85 | 01/31/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH LLC | A STUDY OF LY3556050 IN ADULT PARTICIPANTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1187889614 |
| Principal investigator 1 | Eli Lilly and Company | $872.76 | 01/31/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH LLC | A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-2) | No dispute reported | 06/30/2026 | 1187889714 |
| Principal investigator 1 | Eli Lilly and Company | $728.36 | 01/31/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH LLC | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, DOSE-FINDING STUDY EVALUATING LY3848575 IN CHRONIC NEUROPATHIC PAIN ASSOCIATED WITH DISTAL SENSORY POLYNEUROPATHY | No dispute reported | 06/30/2026 | 1187889716 |
| Principal investigator 1 | Eli Lilly and Company | $445.84 | 01/31/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH LLC | A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES (ATTAIN-2) | No dispute reported | 06/30/2026 | 1187892936 |
| Principal investigator 1 | Eli Lilly and Company | $732.11 | 01/31/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE | No dispute reported | 06/30/2026 | 1187892938 |
| Principal investigator 1 | Eli Lilly and Company | $6,756.06 | 01/31/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH LLC | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187892940 |
| Principal investigator 1 | Amgen Inc. | $30,717.81 | 01/28/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH | A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus | No dispute reported | 06/30/2026 | 1246648850 |
| Principal investigator 1 | Eli Lilly and Company | $185,573.98 | 01/28/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH LLC | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187891076 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $10,608.00 | 01/28/2025 | Non-covered Recipient Entity STUDY METRIX RESEARCH LLC | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease | No dispute reported | 06/30/2026 | 1190307951 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $146.00 | 01/27/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220762475 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6.96 | 01/27/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220762477 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $16.56 | 01/27/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220762479 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $146.00 | 01/27/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762565 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6.96 | 01/27/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762567 |
| Principal investigator 1 | Eli Lilly and Company | $494.10 | 01/27/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH LLC | THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) | No dispute reported | 06/30/2026 | 1187889712 |
| Principal investigator 1 | Eli Lilly and Company | $119,405.00 | 01/27/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH LLC | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 AND TIRZEPATIDE, ALONE OR IN COMBINATION, IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH TYPE 2 DIABETES | No dispute reported | 06/30/2026 | 1187890720 |
| Principal investigator 1 | Eli Lilly and Company | $2,806.01 | 01/27/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH LLC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RETATRUTIDE COMPARED TO TIRZEPATIDE IN ADULTS WHO HAVE OBESITY | No dispute reported | 06/30/2026 | 1187891672 |
| Principal investigator 1 | Eli Lilly and Company | $333,575.00 | 01/27/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH LLC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RETATRUTIDE COMPARED TO TIRZEPATIDE IN ADULTS WHO HAVE OBESITY | No dispute reported | 06/30/2026 | 1187892574 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $55,124.58 | 01/27/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) | No dispute reported | 06/30/2026 | 1190309002 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $764.99 | 01/24/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220813349 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $589.43 | 01/24/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220813351 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,000.00 | 01/24/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220813353 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $785.28 | 01/24/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220813355 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $300.00 | 01/22/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220813347 |
| Principal investigator 1 | Eli Lilly and Company | $37,866.08 | 01/21/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH LLC | THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) | No dispute reported | 06/30/2026 | 1187889710 |
| Principal investigator 1 | Eli Lilly and Company | $395,101.00 | 01/21/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH LLC | A STUDY OF ORFORGLIPRON FOR THE MAINTENANCE OF BODY WEIGHT REDUCTION IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES (ATTAIN-MAINTAIN) | No dispute reported | 06/30/2026 | 1187890166 |
| Principal investigator 1 | Eli Lilly and Company | $116,701.00 | 01/21/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH LLC | PHASE 2 STUDY WITH COMBINATION OF VEMURAFENIB WITH COBIMETINIB IN B-RAF V600E/K MUTATED MELANOMA PATIENTS TO NORMALIZE LDH AND OPTIMIZE NIVOLUMAB AND IPILIMUMAB THERAPY | No dispute reported | 06/30/2026 | 1187890714 |
| Principal investigator 1 | Eli Lilly and Company | $167,761.91 | 01/21/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH LLC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | No dispute reported | 06/30/2026 | 1187891316 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,720.00 | 01/17/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220813411 |
| Principal investigator 1 | Eli Lilly and Company | $55.20 | 01/16/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH LLC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | No dispute reported | 06/30/2026 | 1187890164 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,088.80 | 01/15/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease | No dispute reported | 06/30/2026 | 1190309004 |
| Principal investigator 1 | Eli Lilly and Company | $71,261.32 | 01/13/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH LLC | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187890086 |
| Principal investigator 1 | Eli Lilly and Company | $3,534.12 | 01/09/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH LLC | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187890090 |
| Principal investigator 1 | Eli Lilly and Company | $10,997.85 | 01/09/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH LLC | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 AND TIRZEPATIDE, ALONE OR IN COMBINATION, IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH TYPE 2 DIABETES | No dispute reported | 06/30/2026 | 1187890310 |
| Principal investigator 1 | Eli Lilly and Company | $4,352.69 | 01/09/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH LLC | PHASE 2 STUDY WITH COMBINATION OF VEMURAFENIB WITH COBIMETINIB IN B-RAF V600E/K MUTATED MELANOMA PATIENTS TO NORMALIZE LDH AND OPTIMIZE NIVOLUMAB AND IPILIMUMAB THERAPY | No dispute reported | 06/30/2026 | 1187893348 |
| Principal investigator 1 | Eli Lilly and Company | $130,185.00 | 01/07/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH LLC | A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES (ATTAIN-2) | No dispute reported | 06/30/2026 | 1187890088 |
| Principal investigator 1 | Eli Lilly and Company | $219,033.00 | 01/07/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH LLC | A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-1) | No dispute reported | 06/30/2026 | 1187890168 |
| Principal investigator 1 | Eli Lilly and Company | $125,559.00 | 01/07/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH LLC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | No dispute reported | 06/30/2026 | 1187890170 |
| Principal investigator 1 | Eli Lilly and Company | $206,925.87 | 01/07/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH LLC | A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-2) | No dispute reported | 06/30/2026 | 1187890308 |
| Principal investigator 1 | Eli Lilly and Company | $212,086.00 | 01/07/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH LLC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | No dispute reported | 06/30/2026 | 1187890336 |
| Principal investigator 1 | Eli Lilly and Company | $153,019.77 | 01/07/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE | No dispute reported | 06/30/2026 | 1187891318 |
| Principal investigator 1 | Eli Lilly and Company | $441,539.56 | 01/07/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH LLC | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (TRIUMPH-1) | No dispute reported | 06/30/2026 | 1187892576 |
| Principal investigator 1 | Eli Lilly and Company | $54,145.16 | 01/07/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH LLC | A STUDY OF LY3556050 IN ADULT PARTICIPANTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1187892578 |
| Principal investigator 1 | Eli Lilly and Company | $178,442.00 | 01/07/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH LLC | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, DOSE-FINDING STUDY EVALUATING LY3848575 IN CHRONIC NEUROPATHIC PAIN ASSOCIATED WITH DISTAL SENSORY POLYNEUROPATHY | No dispute reported | 06/30/2026 | 1187892580 |
| Principal investigator 1 | Eli Lilly and Company | $1,504.21 | 01/03/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH LLC | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (TRIUMPH-1) | No dispute reported | 06/30/2026 | 1187889708 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220762445 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220762447 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220762449 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220762451 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762531 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762533 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762535 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762537 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 01/01/2025 | Non-covered Recipient Entity Study Metrix Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220762589 |